English
|
Spanish
Login
Register
For the latest
e
cancer COVID-19 resources, click on this link
Home
News
Journal
Video
e
learning
Conferences
About us
Keyword
Breast
Prostate & urology
Lung & pleura
Colorectal & gastro
Melanoma & skin
Head & neck
Ovary & gynaecology
+
-
Bone
Brain & nervous system
Haematology oncology
Hepatobiliary pancreatic
Paediatric
Neuroendocrine
Sarcomas
Conferences
Sign up for latest coverage
Submit your event
Conferences
e
cancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.
Past
Upcoming
Category
All
Disease Areas
Patient Care
Policy
Prevention & screening
Treatments
Sub-category
All
Region
All
Asia
Middle East and North Africa
Europe
North America
Central America and the Caribbean
South America
Africa
Australia and Oceania
Country
All
Year
All
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
Keyword
ASH 2019
7 - 10 Dec 2019
Orlando, Orlando, United States of America
Videos
News
Treating haematological cancers in Romania
Dr Ciprian Tomuleasa - Ion Chiricuta Clinical Research Center, Cluj Napoca, Rom...
10 Mar 2020
The landscape of haematological cancers in India
Dr Hemant Malhotra - Mahatma Gandhi Medical College Hospital, Jaipur, India
10 Mar 2020
Haematological malignancies: Latest advances from ASH 2019
Dr Eloísa Riva - Hospital de Clínicas, Montevideo, Uruguay
10 Mar 2020
Cancer care in Argentina
Dr Maria Agustina Perusini - Hospital Italiano de Buenos Aires, Buenos Aires, Ar...
10 Mar 2020
VITAL trial: Safety of vosaroxin and infusional cytarabine for frontline treatme...
Dr Stephen Strickland - Vanderbilt University Medical Center, Nashville, USA
27 Jan 2020
Are remissions for AML patients 'better' after daunorubicin and cytarabine lipos...
Prof Daniel Ryan - University of Rochester, Rochester, USA
24 Dec 2019
Is enasidenib plus azacitidine better than with azacitidine alone for AML patien...
Dr Courtney DiNardo - MD Anderson Cancer Center, Houston, USA
24 Dec 2019
PET-Directed therapy for early-stage diffuse large B-cell lymphoma
Prof Daniel Persky - University of Arizona Cancer Center, Tucson, USA
24 Dec 2019
Lenalidomide maintenance for transplant eligible and transplant ineligible newly...
Dr Charlotte Pawlyn - Institute of Cancer Research, London, UK
24 Dec 2019
Dasatinib vs imatinib in the treatment of paediatric ALL
Dr Shuhong Shen - National Children's Medical Center, Shanghai, China
24 Dec 2019
Targeting CD70 with cusatuzumab eliminates acute myeloid leukaemia stem cells in...
Prof Adrian Ochsenbein - University and University Hospital of Bern, Bern, Switz...
19 Dec 2019
Prognostic impact of chromosomal abnormalities and copy number alterations in B-...
Prof Anthony Moorman - Newcastle University, Newcastle, UK
19 Dec 2019
Long-term outcomes of subjects with EBV driven PTLD following solid organ or all...
Dr Sarah Nikiforow - Dana-Farber Cancer Institute, Boston, USA
19 Dec 2019
Clinical outcomes of patients with FLT3-ITD-mutated R/R AML undergoing HSCT afte...
Dr Siddhartha Ganguly - The University of Kansas Health System, Kansas City, USA
19 Dec 2019
Outcomes in patients with therapy-Related AML who achieved remission with CPX-35...
Dr Jeffrey Lancet - H. Lee Moffitt Cancer Center & Research Institute, Tampa, US...
19 Dec 2019
QUANTUM-R: Transfusion independence in patients with FLT3-ITD-mutated R/R AML tr...
Dr Mark Levis - Johns Hopkins Medicine, Baltimore, USA
18 Dec 2019
Safety and efficacy of the novel BTK inhibitor zanubrutinib in patients with CLL...
Prof Constantine Tam - Peter MacCallum Cancer Centre, Melbourne, Australia
18 Dec 2019
Ibrutinib plus venetoclax for the first-line treatment of CLL/SLL: Results from ...
Prof Constantine Tam - Peter MacCallum Cancer Centre, Melbourne, Australia
18 Dec 2019
LYRA: Maintenance therapy with daratumumab improves depth of response and achiev...
Dr Robert Rifkin - Rocky Mountain Cancer Centers, Denver, USA
17 Dec 2019
KRd consolidation in MM patients with a positive PET-CT after standard first-lin...
Dr Fredrik Schjesvold - Oslo University Hospital, Oslo, Norway
17 Dec 2019
ELEVATE TN: Comparing acalabrutinib monotherapy or in combination with obinutuzu...
Dr Jeff Sharman - Willamette Valley Cancer Institute and Research Center, Eugene...
17 Dec 2019
PRIMO: Optimising the dose of duvelisib in patients with R/R peripheral T-cell l...
Dr Steven Horwitz - Memorial Sloan Kettering Cancer Center, New York, USA
17 Dec 2019
Umbralisib, ublituximab and venetoclax in patients with relapsed or refractory c...
Dr Paul Barr - Wilmot Cancer Institute, University of Rochester Medical Center
17 Dec 2019
GLS1 dependency in MYC over-expressing multiple myeloma: New target for therapy?
Dr Salomon Manier - Dana-Farber Cancer Institute, Boston, USA
17 Dec 2019
Predicting early relapse in transplant-eligible MM patients using baseline progn...
Dr Francesca Gay - University of Torino, Torino, Italy
17 Dec 2019
Using multiparameter flow cytometry and next generation sequencing to evaluate M...
Dr Francesca Gay - University of Torino, Torino, Italy
17 Dec 2019
Complete remission after induction chemotherapy determines clinical efficacy of ...
Prof Kristoffer Hellstrand - University of Gothenburg, Gothenburg, Sweden
17 Dec 2019
FiTNEss: Investigating frailty-adjusted therapy in transplant non-eligible patie...
Prof David Cairns - University of Leeds, Leeds, UK
17 Dec 2019
Myeloma highlights from ASH 2019
Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA
13 Dec 2019
Weekly wKRd-D in newly diagnosed multiple myeloma achieves unprecedented results
Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA
13 Dec 2019
FLT3-inhibition in infants with acute lymphoblastic leukaemia
Dr Patrick Brown - Johns Hopkins University, Baltimore, USA
13 Dec 2019
Chronic lymphocytic leukaemia highlights from ASH 2019
Dr John Seymour - Peter MacCallum Cancer Centre, Melbourne, Australia
13 Dec 2019
Benefits of apixaban among venous thromboembolism patients with active cancer
Dr Alexander Cohen - Guys and St Thomas, London, UK
13 Dec 2019
Inotuzumab ozogamicin and chemotherapy with or without blinatumomab in Philadelp...
Dr Nicholas Short - MD Anderson Cancer Center, Houston, USA
13 Dec 2019
Dasatinib vs imatinib for paediatric Ph ALL
Dr Ching-Hon Pui - St Jude's Children's Research Hospital, Memphis, USA
12 Dec 2019
Study of quadruple combination for induction resistant myeloma reveals novel imm...
Dr Yael Cohen - Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
12 Dec 2019
KRd vs KTd followed by carfilzomib maintenance in newly diagnosed MM
Prof Heinz Ludwig - Wilhelmeninen Cancer Research Institute, Vienna, Austria
12 Dec 2019
Updates on REGN1979 in R/R B-cell non-Hodgkins lymphoma
Dr Rajat Bannerji - Rutgers Cancer Institute of New Jersey, New Brunswick, USA
12 Dec 2019
Eligibility criteria in acute myeloid leukaemia clinical trials
Dr Mikkael Sekeres - Cleveland Clinic, Cleveland, USA
12 Dec 2019
Moxetumomab pasudotox-tdfk in heavily retreated r/r hairy cell leukaemia
Dr Robert Kreitman - National Cancer Institute, Bethesda, USA
12 Dec 2019
Azacitidine plus nivolumab in older adults with AML or MDS
Prof Annette Hay - Queen's University, Ontario, Canada
12 Dec 2019
Venetoclax chemo combo active and well-tolerated in children with r/r AML
Dr Seth Karol - St. Jude Children’s Research Hospital, Memphis, USA
12 Dec 2019
Precision medicine treatment in older AML: Results of Beat AML master trial
Dr Amy Burd - Leukemia and Lymphoma Society, White Plains, USA
10 Dec 2019
Older patients with non-Hodgkin lymphoma can be treated successfully with CAR T-...
Dr Karl Kilgore - Avalere Health, Bowie, USA
10 Dec 2019
Depth of response to daratumumab, lenalidomide, bortezomib, and dexamethasone im...
Prof Peter Voorhees - Levine Cancer Institute, Charlotte, USA
10 Dec 2019
CARTITIUDE-1: BCMA-targeted CAR T-cell therapy shows high response rates in pati...
Prof Deepu Madduri - Mount Sinai, New York, USA
10 Dec 2019
Blinatumomab vs chemotherapy as post-reinduction therapy in HR/IR first relapse ...
Dr Patrick Brown - Johns Hopkins University, Baltimore, USA
10 Dec 2019
Identifying prognostic constellations of driver mutations in acute myeloid leuka...
Dr Charles Mullighan - St. Jude Children's Research Hospital, Memphis, USA
10 Dec 2019
CANDOR: Triple drug combo delays disease progression in stubborn multiple myelom...
Dr Saad Usmani - Levine Cancer Institute, Charlotte, USA
10 Dec 2019
Maintenance therapy with CC-486 for acute myeloid leukaemia
Prof Andrew Wei - Monash University, Melbourne, Australia
10 Dec 2019
Daratumuab, carfilzomib and dexamethasone increases survival in patients with re...
Dr Saad Usmani - Levine Cancer Institute, Charlotte, USA
10 Dec 2019
Exploring the pathogenesis of AML and myelodysplastic syndromes using genome and...
Dr Ilaria Iacobucci - St. Jude Children's Research Hospital, Memphis, USA
10 Dec 2019
QUAZAR AML-001: Evaluating CC-486 as a maintenance therapy for older patients wi...
Prof Andrew Wei - Monash University, Melbourne, Australia
10 Dec 2019
Blinatumomab demonstrates superior efficacy compared to chemotherapy in children...
Dr Patrick Brown - Johns Hopkins University, Baltimore, USA
10 Dec 2019
Multiple myeloma highlights from ASH 2019
Prof Heinz Ludwig - Wilhelmeninen Cancer Research Institute, Vienna, Austria
10 Dec 2019
MURANO trial: Venetoclax-rituximab shows sustained benefit in relapsed/refractor...
Dr John Seymour - Peter MacCallum Cancer Centre, Melbourne, Australia
9 Dec 2019
Glasdegib in combination with azacitidine in patients with untreated higher-risk...
Dr Mikkael Sekeres - Cleveland Clinic, Cleveland, USA
9 Dec 2019
Addressing the treatment gap for patients with relapsed/refractory primary syste...
Prof Evangelos Terpos and Prof Efstathios Kastritis
9 Dec 2019
Carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma
Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA
9 Dec 2019
Challenges and importance of long-term treatment for newly diagnosed multiple my...
Prof Sagar Lonial, Prof Meral Beksaç, Dr Robert Rifkin
9 Dec 2019
Novel multi-antigen targeted CAR-NK cell for the treatment of B cell malignancie...
Dr Bahram Valamehr - Fate Therapeutics Inc., San Diego, USA
9 Dec 2019
Multiple myeloma: Anti-BCMA BiTE AMG 701 shows preclinical promise
Dr Yu-Tzu Tai - Dana-Farber Cancer Institute, Boston, USA
8 Dec 2019
Evaluating emerging mutations in patients with acute myeloid leukaemia who relap...
Dr Catherine Smith - University of California San Francisco, San Francisco, USA
8 Dec 2019
Maintenance decitabine after intensive therapy for AML in older FLT3-ITD-negativ...
Dr James Foran - Mayo Clinic Florida, Jacksonville, USA
8 Dec 2019
Bispecific CAR T-cell therapy as treatment for hard to treat multiple myeloma
Dr Yu Hu - Huazhong University of Science and Technology, Wuhan, China
7 Dec 2019
Mosunetuzumab induces complete remissions in poor prognosis non-Hodgkin lymphoma...
Prof Stephen Schuster - University of Pennsylvania, Philadelphia, USA
7 Dec 2019
CAR T-cell therapy in hard-to-treat multiple myeloma produces sustained remissio...
Dr Yu Hu - Huazhong University of Science and Technology, Wuhan, China
7 Dec 2019
Dual-targeted antibody mosunetuzumab elicits durable responses in poor-prognosis...
Prof Stephen Schuster - University of Pennsylvania, Philadelphia, USA
7 Dec 2019
Multiple myeloma patients treated with BCMA-directed CAR T-cell therapy have hig...
Prof Deepu Madduri - Mount Sinai, New York, USA
7 Dec 2019
Cellular immunotherapy for B cell cancers shows promise
Dr Bahram Valamehr - Fate Therapeutics Inc., San Diego, USA
7 Dec 2019
More from
e
cancer